Rapamycin, in combination with etoposide, decreased the engraftment activity of human LSCs from AML patients [91], while a dual PI3K/mTOR inhibitor, PI-103, targeted the CD34+/CD38−/CD123+ AML subpopulation which is enriched in LSCs [105]. Here, CD38 is linked to acute myeloid leukemia.